Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Viktoria Blumenberg, Maryam Kazerani, Tobias Straub, Francesco Corrado, Vadim Borisov, Stephan Baumann, Galina Busch, Jan Wulf, Agnese Petrera, Kai Rejeski, Christian Schmidt, Benjamin Tast, Michael von Bergwelt-Baildon, Christoph Stein-Thöringer, Veit L. Buecklein, Marion Subklewe

Blood (2024) 144 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2024-208938

Published: 2024

Journal Articles

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2024) 144 (Supplement 1): 240.

https://doi.org/10.1182/blood-2024-200735

Published: 2024

Journal Articles

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Blood (2024) 144 (Supplement 1): 237.

https://doi.org/10.1182/blood-2024-201441

Published: 2024

Journal Articles

Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III

Stephanie Herold, Anke Ohler, Marie-Kristin Tilch, Christian Schmidt, Michael Unterhalt, Eva Hoster, Elisabeth Hoenig, Susanne Singer, Carlo Visco, Marco Ladetto, Alessandra Tucci, Christiane Pott, Georg Hess, Martin Dreyling

Blood (2024) 144 (Supplement 1): 3042.2.

https://doi.org/10.1182/blood-2024-204691

Published: 2024

Journal Articles

Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)

Marie-Kristin Tilch, Christian Schmidt, Marek Trneny, Eva Gine, Olivier Hermine, Anke Ohler, Stephanie Herold, Marta Illenyi, Eva Hoster, Christiane Pott, Martin Dreyling, Georg Hess

Blood (2024) 144 (Supplement 1): 4422.3.

https://doi.org/10.1182/blood-2024-206931

Published: 2024

Journal Articles

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Blood (2023) 142 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2023-186510

Published: 2023

Journal Articles

Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL

Viktoria Blumenberg, Maryam Kazerani, Stephan Baumann, Tobias Straub, Francesco Corrado, Jan Wulf, Galina Busch, Kai Rejeski, Lisa Frölich, Christian Schmidt, Michael von Bergwelt-Baildon, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2023-187495

Published: 2023

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

Kai Rejeski, Zhijie Wu, Viktoria Blumenberg, Wolfgang G. Kunz, Susanna Müller, Sachiko Kajigaya, Shouguo Gao, Veit L. Bücklein, Lisa Frölich, Christian Schmidt, Michael von Bergwelt-Baildon, Xingmin Feng, Neal S. Young, Marion Subklewe

Blood (2022) 140 (20): 2175–2179.

https://doi.org/10.1182/blood.2022017015

Published: 2022

Includes: Supplemental data

Journal Articles

Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy

Kai Rejeski, David M. Cordas dos Santos, Paul Trinkner, Sophie Guenther, Lian Liu, Michael Winkelmann, Veit L Buecklein, Viktoria Blumenberg, Christian Schmidt, Philipp Karschnia, Wolfgang G. Kunz, Michael von Bergwelt, Sebastian Theurich, Marion Subklewe

Blood (2022) 140 (Supplement 1): 10405–10406.

https://doi.org/10.1182/blood-2022-159493

Published: 2022

Journal Articles

Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)

Veit L Buecklein, Maximilian Warm, Karsten Spiekermann, Christian Schmidt, Michael Unterhalt, Naval Daver, Marion Subklewe

Blood (2022) 140 (Supplement 1): 3227–3228.

https://doi.org/10.1182/blood-2022-169867

Published: 2022

Journal Articles

Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Eva Hoster, Marie-Helene Delfau, Elizabeth A. Macintyre, Linmiao Jiang, Stephan Stilgenbauer, Ursula Vehling-Kaiser, Gilles Salles, Catherine Thieblemont, Hervé Tilly, Lothar Kanz, Pierre Feugier, Kai Huebel, Christian Schmidt, Vincent Ribrag, Hanneke Kluin-Nelemans, Martin Dreyling, Christiane Pott

Blood (2022) 140 (Supplement 1): 1304–1306.

https://doi.org/10.1182/blood-2022-159932

Published: 2022

Journal Articles

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Blood (2022) 140 (Supplement 1): 7522–7523.

https://doi.org/10.1182/blood-2022-168874

Published: 2022

Journal Articles

Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Kai Rejeski, Viktoria Blumenberg, Simon KG Forsberg, Agnese Petrera, Niklas Mueller, Friederike Hildebrandt, Lisa Frölich, Philipp Karschnia, Christian Schmidt, Martin Dreyling, Michael von Bergwelt, Marion Subklewe, Veit L Buecklein

Blood (2022) 140 (Supplement 1): 7421–7422.

https://doi.org/10.1182/blood-2022-167806

Published: 2022

Journal Articles

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 287–288.

https://doi.org/10.1182/blood-2022-159357

Published: 2022

Journal Articles

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2022) 140 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2022-163018

Published: 2022

Journal Articles

Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Blood (2022) 140 (Supplement 1): 2411–2413.

https://doi.org/10.1182/blood-2022-165452

Published: 2022

Journal Articles

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Blood (2021) 138 (24): 2499–2513.

https://doi.org/10.1182/blood.2020010543

Published: 2021

Includes: Supplemental data

Journal Articles

The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma: A Long Term Pooled Trials Analysis

Luca Fischer, Linmiao Jiang, Joerg Bittenbring, Kai Hübel, Christian Schmidt, Johannes Duell, Bernd Metzner, Jürgen Krauter, Bertram Glass, Andreas Hüttmann, Kerstin Schaefer-Eckart, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Martin H. Dreyling, Eva Hoster

Blood (2021) 138 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2021-148074

Published: 2021

Journal Articles

Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Gloria Iacoboni, Kai Rejeski, Lina Camacho, Annalisa Chiappella, Serafina Guadagnuolo, Lucía López Corral, Mariana Bastos-Oreiro, Javier Delgado Serrano, Christian Schmidt, Cecilia Carpio, Juan Luis Reguera, Mi Kwon, Alejandro Martín García-Sancho, Pier Luigi Zinzani, Paolo Corradini, Marion Subklewe, Pere Barba

Blood (2021) 138 (Supplement 1): 2827.

https://doi.org/10.1182/blood-2021-153087

Published: 2021

NARROW

Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy

Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)

Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma: A Long Term Pooled Trials Analysis

Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only